Kurs & Likviditet
|2023-01-12||Ordinarie utdelning NEWBRY 0.00 SEK|
|Lista||First North Stockholm|
|Industri||Läkemedel & Handel|
Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Lenalidomide Newbury in Sweden as the first country in a Scandinavian registration procedure. Approvals in Denmark and Norway are expected to follow upon finalized national reviews.
Lenalidomide is a prescription drug used to treat multiple myeloma and several other haematological malignancies. Lenalidomide is an immunomodulatory treatment and is taken as a capsule, once daily. The originator Revlimid is marketed in Sweden by Celgene – a BMS company and sales is estimated to be 1,4 billion SEK across Scandinavia in 2021 (source: DLMI Nordic Pharma Insights)
“We are pleased to see our portfolio of oncology products being approved by the Health Authorities. The approval of Lenalidomide Newbury is another regulatory milestone and we expect additional product approvals during the coming years”, says Lars Minor - CEO, Newbury Pharmaceuticals.
Lenalidomide Newbury is part of the oncology pipeline with 11 products expected to be registered in the years ahead. Oncology treatment costs are a big part of the total treatment costs for society and the future launch of Lenalidomide will support efficient use of resources and free-up reserves for new innovative products.